As more people take GLP-1 medications to lose weight, doctors are learning more about both the benefits and the risks
In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]
PMID: 23558240 Korashy H.M, El-Kadi A.O
At the pathophysiological level, it is now clear that most narcolepsy cases with cataplexy, and a minority of cases (530 %) without cataplexy or with atypical cataplexy-like symptoms, are caused by a lack of hypocretin (orexin) of likely an autoimmune origin
Galactose ligand at high concentration decreased the internalization of nanoparticles in GLUT-1 expressing lung epithelial and human nasopharyngeal epidermal carcinoma cell lines [63]
Necroptosis and parthanatos are involved in remote lung injury after receiving ischemic renal allografts in rats